Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2014

Open Access 01-12-2014 | Research

Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA

Authors: Hsiang-Yu Lin, Chih-Kuang Chuang, Ming-Ren Chen, Pao Chin Chiu, Yu-Yuan Ke, Dau-Ming Niu, Fuu-Jen Tsai, Wuh-Liang Hwu, Ju-Li Lin, Shuan-Pei Lin

Published in: Orphanet Journal of Rare Diseases | Issue 1/2014

Login to get access

Abstract

Background

Mucopolysaccharidosis IVA (MPS IVA) is a rare lysosomal storage disorder caused by N-acetylgalactosamine-6-sulfatase deficiency, which catalyzes a step in the catabolism of glycosaminoglycans, keratan sulfate and chondroitin-6-sulfate. This disease has a variable age of onset and rate of progression.

Methods

A retrospective analysis of medical records of 24 patients with MPS IVA (11 males, 13 females; current mean age ± SD, 12.6 ± 6.6 years; age range, 1.4-29.4 years) seen at 6 medical centers in Taiwan from January 1996 through June 2013 was performed.

Results

Mean ages of onset of symptoms and confirmed diagnosis were 2.0 ± 1.6 and 5.7 ± 4.5 years, respectively. The most prevalent clinical manifestations were kyphosis (100%), pectus carinatum (96%), abnormal gait (93%), striking short trunk dwarfism (92%), genu valgum (92%), and valvular heart disease (91%). Eight patients (33%) experienced at least one surgical procedure with the most common being ear tube insertion (25%), adenoidectomy (17%), tonsillectomy (13%), supraglottoplasty (13%), spinal decompression (13%), and spinal fusion (13%). The most prevalent cardiac valve abnormalities were aortic stenosis (45%) and mitral regurgitation (45%). At the time of the study, 8 out of 24 patients (33%) have died at the mean age of 17.2 ± 7.7 years.

Conclusions

An understanding of the natural history involved in MPS IVA may allow early diagnosis of the disease. All affected Taiwanese patients experienced significant functional limitations. Adequate evaluations and timely management may improve clinical outcomes and quality of life.
Appendix
Available only for authorised users
Literature
1.
go back to reference Neufeld EF, Muenzer J: The mucoplysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B. New York: McGraw-Hill; 2001: 3421-3452. Neufeld EF, Muenzer J: The mucoplysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B. New York: McGraw-Hill; 2001: 3421-3452.
2.
go back to reference Chuang CK, Lin SP: Neurochemical changes and therapeutical approaches in mucopolysaccharidoses. Neurochemistry of Metabolic Diseases-Lysosomal storage diseases, phenylketouria and Canavan disease. Edited by: Sankar S, Michael A, Maheep B. Trivandrum, India: Transworld Research Network; 2007: 1-20. Chuang CK, Lin SP: Neurochemical changes and therapeutical approaches in mucopolysaccharidoses. Neurochemistry of Metabolic Diseases-Lysosomal storage diseases, phenylketouria and Canavan disease. Edited by: Sankar S, Michael A, Maheep B. Trivandrum, India: Transworld Research Network; 2007: 1-20.
3.
go back to reference Northover H, Cowie RA, Wraith JE: Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 1996, 19: 357-365. 10.1007/BF01799267.CrossRefPubMed Northover H, Cowie RA, Wraith JE: Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 1996, 19: 357-365. 10.1007/BF01799267.CrossRefPubMed
4.
go back to reference Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T: International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007, 30: 165-174. 10.1007/s10545-007-0529-7.CrossRefPubMed Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T: International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007, 30: 165-174. 10.1007/s10545-007-0529-7.CrossRefPubMed
5.
go back to reference Hendriksz C, Vellodi A, Jones S, Takkele H, Lee S, Chesler S: Long Term Outcomes of a Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome). Mol Genet Metab. 2012, 105: S35.CrossRef Hendriksz C, Vellodi A, Jones S, Takkele H, Lee S, Chesler S: Long Term Outcomes of a Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome). Mol Genet Metab. 2012, 105: S35.CrossRef
6.
go back to reference Nelson J: Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997, 101: 355-358. 10.1007/s004390050641.CrossRefPubMed Nelson J: Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997, 101: 355-358. 10.1007/s004390050641.CrossRefPubMed
7.
go back to reference Nelson J, Crowhurst J, Carey B, Greed L: Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A. 2003, 123A: 310-313. 10.1002/ajmg.a.20314.CrossRefPubMed Nelson J, Crowhurst J, Carey B, Greed L: Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A. 2003, 123A: 310-313. 10.1002/ajmg.a.20314.CrossRefPubMed
8.
go back to reference Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ: Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. Am J Med Genet A. 2009, 149A: 960-964. 10.1002/ajmg.a.32781.CrossRefPubMed Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ: Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. Am J Med Genet A. 2009, 149A: 960-964. 10.1002/ajmg.a.32781.CrossRefPubMed
9.
go back to reference Lee NH, Cho SY, Maeng SH, Jeon TY, Sohn YB, Kim SJ: Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA. Korean J Pediatr. 2012, 55: 430-437. 10.3345/kjp.2012.55.11.430.CrossRefPubMedPubMedCentral Lee NH, Cho SY, Maeng SH, Jeon TY, Sohn YB, Kim SJ: Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA. Korean J Pediatr. 2012, 55: 430-437. 10.3345/kjp.2012.55.11.430.CrossRefPubMedPubMedCentral
10.
go back to reference Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R: The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013, 109: 54-61. 10.1016/j.ymgme.2013.01.021.CrossRefPubMed Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R: The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013, 109: 54-61. 10.1016/j.ymgme.2013.01.021.CrossRefPubMed
11.
go back to reference Chuang CK, Lin SP, Chung SF: Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. Zhonghua Yi Xue Za Zhi (Taipei). 2001, 64: 15-22. Chuang CK, Lin SP, Chung SF: Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. Zhonghua Yi Xue Za Zhi (Taipei). 2001, 64: 15-22.
12.
go back to reference Chen W, Chang MH: New growth charts for Taiwanese children and adolescents based on World Health Organization standards and health-related physical fitness. Pediatr Neonatol. 2010, 51: 69-79. 10.1016/S1875-9572(10)60014-9.CrossRefPubMed Chen W, Chang MH: New growth charts for Taiwanese children and adolescents based on World Health Organization standards and health-related physical fitness. Pediatr Neonatol. 2010, 51: 69-79. 10.1016/S1875-9572(10)60014-9.CrossRefPubMed
13.
go back to reference Chen MR, Lin SP, Hwang HK, Yu CH: Cardiovascular changes in mucopolysaccharidoses in Taiwan. Acta Cardiol. 2005, 60: 51-53. 10.2143/AC.60.1.2005049.CrossRefPubMed Chen MR, Lin SP, Hwang HK, Yu CH: Cardiovascular changes in mucopolysaccharidoses in Taiwan. Acta Cardiol. 2005, 60: 51-53. 10.2143/AC.60.1.2005049.CrossRefPubMed
14.
go back to reference Henry WL, Gardin JM, Ware JH: Echocardiographic measurements in normal subjects from infancy to old age. Circulation. 1980, 62: 1054-1061. 10.1161/01.CIR.62.5.1054.CrossRefPubMed Henry WL, Gardin JM, Ware JH: Echocardiographic measurements in normal subjects from infancy to old age. Circulation. 1980, 62: 1054-1061. 10.1161/01.CIR.62.5.1054.CrossRefPubMed
15.
go back to reference American Thoracic Society: Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med. 1995, 152: 1107-1136.CrossRef American Thoracic Society: Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med. 1995, 152: 1107-1136.CrossRef
17.
go back to reference Lin SP, Shih SC, Chuang CK, Lee KS, Chen MR, Niu DM: Characterization of pulmonary function impairments in patients with mucopolysaccharidoses-changes with age and treatment. Pediatr Pulmonol. 2013, doi: 10.1002/ppul.22774. Lin SP, Shih SC, Chuang CK, Lee KS, Chen MR, Niu DM: Characterization of pulmonary function impairments in patients with mucopolysaccharidoses-changes with age and treatment. Pediatr Pulmonol. 2013, doi: 10.1002/ppul.22774.
19.
go back to reference Lin HY, Shih SC, Chuang CK, Chen MR, Niu DM, Lin SP: Assessment of Bone Mineral Density by Dual Energy X-ray Absorptiometry in Patients with Mucopolysaccharidoses. Orphanet J Rare Dis. 2013, 8: 71. 10.1186/1750-1172-8-71.CrossRefPubMedPubMedCentral Lin HY, Shih SC, Chuang CK, Chen MR, Niu DM, Lin SP: Assessment of Bone Mineral Density by Dual Energy X-ray Absorptiometry in Patients with Mucopolysaccharidoses. Orphanet J Rare Dis. 2013, 8: 71. 10.1186/1750-1172-8-71.CrossRefPubMedPubMedCentral
20.
go back to reference Lin HY, Chen MR, Lin CC, Chen CP, Lin DS, Chuang CK: Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol. 2010, 45: 1205-1212. 10.1002/ppul.21309.CrossRefPubMed Lin HY, Chen MR, Lin CC, Chen CP, Lin DS, Chuang CK: Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol. 2010, 45: 1205-1212. 10.1002/ppul.21309.CrossRefPubMed
21.
go back to reference Jones SA, Almássy Z, Beck M, Burt K, Clarke JT, Giugliani R: Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009, 32: 534-543. 10.1007/s10545-009-1119-7.CrossRefPubMed Jones SA, Almássy Z, Beck M, Burt K, Clarke JT, Giugliani R: Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009, 32: 534-543. 10.1007/s10545-009-1119-7.CrossRefPubMed
22.
go back to reference Shih SL, Lee YJ, Lin SP, Sheu CY, Blickman JG: Airway changes in children with mucopolysaccharidoses. Acta Radiol. 2002, 43: 40-43.CrossRefPubMed Shih SL, Lee YJ, Lin SP, Sheu CY, Blickman JG: Airway changes in children with mucopolysaccharidoses. Acta Radiol. 2002, 43: 40-43.CrossRefPubMed
23.
go back to reference Hendriksz CJ, Al-Jawad M, Berger KI, Hawley SM, Lawrence R, Mc Ardle C: Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis. 2013, 36: 309-322. 10.1007/s10545-012-9459-0.CrossRefPubMedPubMedCentral Hendriksz CJ, Al-Jawad M, Berger KI, Hawley SM, Lawrence R, Mc Ardle C: Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis. 2013, 36: 309-322. 10.1007/s10545-012-9459-0.CrossRefPubMedPubMedCentral
24.
go back to reference James A, Hendriksz CJ, Addison O: The oral health needs of children, adolescents and young adults affected by a mucopolysaccharide disorder. JIMD Rep. 2012, 2: 51-58.CrossRefPubMedPubMedCentral James A, Hendriksz CJ, Addison O: The oral health needs of children, adolescents and young adults affected by a mucopolysaccharide disorder. JIMD Rep. 2012, 2: 51-58.CrossRefPubMedPubMedCentral
25.
go back to reference McDonald A, Steiner R, Kuehl K, Turbeville S: Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr Rehabil Med. 2010, 3: 119-127.PubMed McDonald A, Steiner R, Kuehl K, Turbeville S: Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr Rehabil Med. 2010, 3: 119-127.PubMed
26.
go back to reference Li AM, Yin J, Au JT, So HK, Tsang T, Wong E: Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med. 2007, 176: 174-180. 10.1164/rccm.200607-883OC.CrossRefPubMed Li AM, Yin J, Au JT, So HK, Tsang T, Wong E: Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med. 2007, 176: 174-180. 10.1164/rccm.200607-883OC.CrossRefPubMed
27.
go back to reference Lammers AE, Hislop AA, Flynn Y, Haworth SG: The 6-minute walk test: normal values for children of 4–11 years of age. Arch Dis Child. 2008, 93: 464-468. 10.1136/adc.2007.123653.CrossRefPubMed Lammers AE, Hislop AA, Flynn Y, Haworth SG: The 6-minute walk test: normal values for children of 4–11 years of age. Arch Dis Child. 2008, 93: 464-468. 10.1136/adc.2007.123653.CrossRefPubMed
28.
go back to reference ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002, 166: 111-117.CrossRef ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002, 166: 111-117.CrossRef
29.
go back to reference Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC: Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008, 94: 469-475. 10.1016/j.ymgme.2008.04.001.CrossRefPubMed Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC: Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008, 94: 469-475. 10.1016/j.ymgme.2008.04.001.CrossRefPubMed
30.
go back to reference Danes BS: Corneal clouding in the genetic mucopolysaccharidoses: a cell culture study. Clin Genet. 1973, 4: 1-7.CrossRefPubMed Danes BS: Corneal clouding in the genetic mucopolysaccharidoses: a cell culture study. Clin Genet. 1973, 4: 1-7.CrossRefPubMed
31.
go back to reference Couprie J, Denis P, Guffon N, Reynes N, Masset H, Beby F: Ocular manifestations in patients affected by Morquio syndrome (MPS IV). J Fr Ophtalmol. 2010, 33: 617-622. 10.1016/j.jfo.2010.09.008.CrossRefPubMed Couprie J, Denis P, Guffon N, Reynes N, Masset H, Beby F: Ocular manifestations in patients affected by Morquio syndrome (MPS IV). J Fr Ophtalmol. 2010, 33: 617-622. 10.1016/j.jfo.2010.09.008.CrossRefPubMed
32.
go back to reference Schleier E, Streubel HG: Phoniatric aspects of children with mucopolysaccharidosis. Folia Phoniatr (Basel). 1976, 28: 65-72. 10.1159/000264033.CrossRef Schleier E, Streubel HG: Phoniatric aspects of children with mucopolysaccharidosis. Folia Phoniatr (Basel). 1976, 28: 65-72. 10.1159/000264033.CrossRef
Metadata
Title
Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA
Authors
Hsiang-Yu Lin
Chih-Kuang Chuang
Ming-Ren Chen
Pao Chin Chiu
Yu-Yuan Ke
Dau-Ming Niu
Fuu-Jen Tsai
Wuh-Liang Hwu
Ju-Li Lin
Shuan-Pei Lin
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2014
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-9-21

Other articles of this Issue 1/2014

Orphanet Journal of Rare Diseases 1/2014 Go to the issue